LAWRENCEVILLE, N.J., May 30, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today that Professor Riccardo Lencioni, MD, FSIR, EBIR, the Director of the Division of Diagnostic Imaging and Intervention at Pisa University School of Medicine in Italy, ECIO President and Lead European Principal Investigator for Celsion's Phase III HEAT Study will, in conjunction with two separate scientific presentations, review the clinical trial results including new emerging findings from the HEAT Study post hoc analysis at the 4th European Conference on Interventional Oncology, which is being held June 19-22, 2013 in Budapest, Hungary. Dr. Lencioni will make two presentations on hepatocellular carcinoma (HCC) and related advances in interventional management.
- Dr. Lencioni's first presentation, titled "New Interventional Oncology Approaches in HCC; An Update on Clinical Trials" will be held Wednesday, June 19, 2013 at 2:30 p.m. (local time) in Plenary Session: Open Issues in the Management of Liver Cancer. This presentation is part of a joint symposium of the ECIO and the International Liver Cancer Association (ILCA). This special event will be chaired by Dr. Lencioni (ECIO President) and Dr. Joseph Llovet (ILCA President).
- His second presentation, titled "Thermally Sensitive Doxorubicin Carriers" will be held Thursday, June 20, 2013 at 10:30 a.m. (local time) in Plenary Session: New Horizons in Interventional Oncology.
"I am pleased to present this post-hoc analysis of a large subgroup of patients from the Phase III HEAT Study to the European and international interventional oncology community which may be indicating a meaningful clinical benefit in both progression free survival (PFS) and overall survival (OS) in patients who received an optimized RFA procedure," said Professor Lencioni. "It is important to note that the duration of heat from the RFA procedure is a key factor in a successful clinical outcome when combined with ThermoDox® as suggested by this analysis. These findings are very encouraging and consistent with our understanding of how RFA plus ThermoDox® can potentially offer an important new treatment for this underserved patient population."
Celsion has conducted a comprehensive analysis of the data from the Phase III HEAT Study of ThermoDox® in HCC, also known as primary liver cancer, with key principal investigators, data experts and liver cancer experts including Professor Lencioni. Emerging data from the HEAT Study post hoc analysis demonstrates that ThermoDox® markedly improves PFS and overall survival in patients if their lesions undergo RFA for 45 minutes or more. These findings apply to HCC lesions from both size cohorts of the HEAT Study (3-5 cm and 5-7 cm) and represent a sizable subgroup of approximately 300 patients.
About Celsion Corporation
Celsion is dedicated to the development and commercialization of innovative cancer drugs, including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. Celsion has research, license or commercialization agreements with leading institutions, including the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford. For more information on Celsion, visit our website: http://www.celsion.com.
Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the significant expense, time, and risk of failure of conducting clinical trials; HEAT Study data is subject to further verification and review by the HEAT Study Data Management Committee; the need for Celsion to evaluate its future development plans; termination of the Technology Development Contract or collaboration between Celsion and HISUN at any time; possible acquisitions or licenses of other technologies, assets or businesses or the possible failure to make such acquisitions or licenses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Celsion 's periodic reports and prospectuses filed with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Investor Contact Jeffrey W. Church Senior Vice President – Corporate Strategy and Investor Relations 609-482-2455 firstname.lastname@example.org
SOURCE Celsion Corporation